

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: G01N 27/327, 27/333, 33/50, 33/574, 33/68, 33/96	A1	(11) International Publication Number: WO 97/29366 (43) International Publication Date: 14 August 1997 (14.08.97)
(21) International Application Number: PCT/AU97/00071 (22) International Filing Date: 10 February 1997 (10.02.97) (30) Priority Data: 60/011,314 8 February 1996 (08.02.96) US (71) Applicants (for all designated States except US): AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RESEARCH INSTITUTE [AU/AU]; 126 Greville Street, Chatswood, NSW 2067 (AU). THE UNIVERSITY OF SYDNEY [AU/AU]; Sydney, NSW 2006 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): BRAACH-MAKSVYTIS, Vijoleta, Lucija, Bronislava [AU/AU]; 9 Darley Street, Dulwich Hills, NSW 2203 (AU). CORNELL, Bruce, Andrew [AU/AU]; 58 Wycombe Road, Neutral Bay, NSW 2089 (AU). THOMSON, David, Geoffrey [AU/AU]; 19 Konin-deric Parade, Narara, NSW 2250 (AU). RAGUSE, Burkhard [DE/AU]; 2 Mudies Road, St. Ives, NSW 2075 (AU). (74) Agent: F.B. RICE & CO.; 28A Montague Street, Balmain, NSW 2041 (AU).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: ENZYME DETECTION BIOSENSORS (57) Abstract The present invention provides a biosensor for use in detecting the presence of an enzyme or enzymes in a sample. The biosensor comprises a membrane and means for determining the impedance of the membrane. The membrane includes ionophores therein to which are attached linkers. The linkers are cleavable by the enzyme or enzymes to be detected, with the cleavage of the linker causing a change in the ability of ions to pass through the membrane via the ionophores.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Enzyme Detection Biosensors

The present invention relates to biosensors and methods involving the use of these biosensors in detecting the presence of enzymes by
5 detecting their enzymatic activity.

A number of proteins which are useful as immunodiagnostic analytes and disease markers have the additional property of enzymatic activity, in particular protease activity. In addition, other classes of proteins exhibit nuclease activity.

10 Prostate Specific Antigen (PSA), a diagnostic marker for prostate cancer, is an example of a protein which exhibits protease activity, and belongs to the class of proteins known as the serine proteases. Examples of other proteases which are important immunodiagnostic markers include blood coagulation enzymes, elastase, cathepsin B.

15 There are also a number of important industrial enzymes such as subtilisin, papain and α -amylase.

Examples of important nucleases are restriction enzymes, e.g., BamH1, *Hind* III, polymerases which can act as nucleases under certain conditions, e.g., T4 DNA polymerase, reverse transcriptase, which acts as an
20 Rnase under certain conditions, e.g., Rnase H, and exo- and endo-nucleases, e.g., S1 nuclease.

Current diagnostic tests employ immunoassays for the detection of PSA (e.g. a number of analytical instruments such as Abbott's AXsym, Boehringer Mannheim's Elecsys, and CIBA-Corning's ACS-180, all have
25 ELISA-based PSA tests). These tests use antibodies raised against the PSA molecule which recognise the specific epitope sites within the protein molecule.

A variation on these approaches is disclosed in International Patent application No. PCT/AU95/00536. In this reference there is disclosed a range
30 of substrates specifically cleaved by PSA. There is also disclosure in this reference of an assay system for proteases such as PSA which make use of the activity of the protease. This assay system involves the use of a ligand to capture the PSA and the subsequent use of a substrate for the PSA.

The present inventors have developed devices and methods for the
35 detection of enzymes which make use of the protein's protease activity. These devices and methods involve the use of membrane based biosensors.

Information regarding such biosensors can be found in International Patent Application Nos PCT/AU88/00273, PCT/AU89/00352, PCT/AU90/00025, PCT/AU92/00132, PCT/AU93/00509, PCT/AU93/00620, PCT/AU94/00202 and PCT/AU95/00763. The disclosure of each of these applications is included
5 herein by reference.

The present invention involves providing a substrate for the enzyme to be detected and then sensing the digestion of the substrate by the enzyme. This may be achieved in a number of ways, for example the digestion of the substrate may remove a group from the ionophore thereby releasing the
10 ionophore so that it diffuses laterally within the membrane or may result in an increase in the ability of ions to pass through the ionophore simply by a reduction in "steric" hindrance. Alternatively the digestion of the substrate when attached to a membrane spanning component may result in the release of the ionophore such that it may diffuse laterally within the membrane.
15 Clearly this could also be achieved by digestion of substrates attached to both the ionophore and membrane spanning component.

In another arrangement the digestion of the substrate results in the release of ionophore including probe which then inserts itself into the membrane.

20 Accordingly, in a first aspect the present invention consists in a biosensor for use in detecting the presence of an enzyme in a sample, the biosensor comprising a membrane and means for determining the impedance of the membrane, the membrane having ionophores therein to which are attached linkers, the linkers being cleavable by the enzyme to be
25 detected, the cleavage of the linker causing a change in the ability of ions to pass through the membrane via the ionophores.

In a preferred embodiment of the present invention the linker is attached to the membrane such that the ionophore is prevented from diffusing laterally within the membrane. It is preferred that the linker is
30 attached to membrane spanning components provided in the membrane. This attachment may be achieved in a number of ways such as covalent attachment, however, it is presently preferred that the attachment is achieved by providing on each of the linker and membrane spanning component one member of a ligand binding pair. A preferred ligand binding
35 pair is biotin streptavidin. In another preferred arrangement both the membrane spanning component and the linker are provided with moieties

which are both bound to the same molecule, for example biotin is provided on both the membrane spanning component and the linker and there is cross-linking via streptavidin.

5 The moiety on the membrane spanning component may also be attached via a linker. This may be the same linker as that provided on the ionophore or may be different.

10 In a further preferred embodiment the membrane comprises a first and second layer of a closely packed array of amphiphilic molecules, a plurality of ionophores and a plurality of membrane-spanning lipids prevented from lateral diffusion in the membrane, the ionophores comprising first and second half membrane spanning monomers, the first half membrane spanning monomers being provided in the first layer and the second half membrane spanning monomers being provided in the second layer. the first half membrane spanning monomers being prevented from
15 lateral diffusion in the first layer, the second half membrane spanning monomers being linked to the membrane spanning lipids via the linker. Following cleavage of the linker by the enzyme the second half membrane spanning monomers can diffuse laterally within the second layer independent of the first half membrane spanning monomers.

20 In a second aspect the present invention consists in a biosensor for use in detecting the presence of an enzyme in a sample, the biosensor comprising a membrane and means for determining the impedance of the membrane, the membrane having a plurality of ionophores and a plurality of membrane-spanning components therein, the membrane-spanning components having attached thereto linker molecules to which are
25 connected the ionophores, the linker molecules being cleavable by the enzyme to be detected, the cleavage of the linker molecules causing a change in the ability of ions to pass through the membrane via the ionophores.

30 In a preferred embodiment the membrane comprises a first and second layer of a closely packed array of amphiphilic molecules and the membrane-spanning components are prevented from lateral diffusion in the membrane. Preferably the ionophores comprise first and second half membrane spanning monomers. the first half membrane spanning monomers
35 being provided in the first layer and the second half membrane spanning monomers being provided in the second layer with the first half membrane

spanning monomers being prevented from lateral diffusion in the first layer. The second half membrane spanning monomers are connected to the membrane-spanning components via the linker molecule.

5 The ionophores in both these aspects are preferably gramicidin or analogues thereof.

While a range of enzymes can be detected using the biosensor or the present invention the biosensor is particularly useful in the detection of proteases, in particular those of clinical importance such as PSA, fibrinogen etc.

10 In a third aspect the present invention consists in a biosensor for the detection of enzymes comprising first and second zones, means to allow addition of a sample suspected to contain an enzyme to the first zone, the first zone containing a probe linked to a carrier via a linker cleavable by the enzyme and means to allow passage of unlinked probe from the first zone to
15 the second zone; the second zone including a membrane the impedance of which is dependent on the presence or absence of the probe and means to measure the impedance of the membrane.

In a preferred embodiment of this aspect of the present invention the membrane comprises a first and a second layer of a closely packed array of
20 amphiphilic molecules and a plurality of ionophores comprising a first and second half membrane spanning monomers, the first half membrane spanning monomers being provided in the first layer and the second half membrane spanning monomers being provided in the second layer, the second half membrane spanning monomers being capable of lateral diffusion
25 within the second layer independent of the first half membrane spanning monomers, the first half membrane spanning monomers being prevented from lateral diffusion in the first layer, and a ligand provided on at least the second half membrane spanning monomers, said ligand being reactive with the probe or a portion thereof, the binding of the probe to the ligand causing
30 a change in the relationship between the first half membrane spanning monomers and the second half membrane spanning monomers such that the flow of ions across the membrane via the ionophores is allowed or prevented.

35 In a preferred embodiment the probe includes streptavidin and the ligand includes biotin.

In yet another preferred embodiment the probe includes an ionophore such that when the probe comes into contact with the membrane the ionophore inserts itself into the membrane changing the impedance of the membrane. As an example of such an arrangement the probe may include valinomycin which inserts itself into the membrane.

In a preferred embodiment of the present invention the enzyme to be detected is a protease in particular Prostate Specific Antigen. In this case it is preferred that the linker or linker molecule includes the sequence Ala-Val-Tyr.

As will be recognised by those skilled in the art the actual linker used will depend on the enzyme to be detected. Examples of some enzymes and their corresponding substrates are set out in Whittaker *et al.* Analytical Biochemistry: 220, 238-243 (1994), the disclosure of which is incorporated by cross-reference.

In a further aspect the present invention consists in a method of detecting the presence of an enzyme in a sample comprising adding the sample to the biosensor of the first or second or third aspect of the present invention and measuring the change in impedance of the membrane.

As will be readily apparent the biosensors and methods of the present invention do not detect total enzyme: they detect only active enzyme. This is important as in a number of situations it is the amount of active enzyme present which is of importance not simply the total amount of enzyme present as would be measured in a standard sandwich ELISA.

It will also be apparent that the sensors of the present invention can be used to detect a wide range of enzymes. These enzymes include nucleases, protease amylases etc. The sensors are adapted to the particular enzyme to be detected by adjusting the make-up of the linker. For example to detect proteases the linker will typically include a peptide portion which is cleaved by the enzyme. Information regarding peptide sequences cleaved by specific proteases is provided in Whittaker *et al* referred to above. Where the enzyme to be detected is a nuclease the linker will typically include a nucleic acid sequence. Information regarding specific sequences cleaved by specific enzymes can be found in "Current Protocols in Molecular Biology" Ausubel *et al* (1987) John Wiley & Sons, NY.

The sensors of the present invention may also find use in drug development for determining DNA-drug binding sites. The sensors could

also be used in determining DNA-protein binding sites. The sensors may also find use in diagnosing infection. For example the sensors could be used to detect enzyme activity specifically associated with a pathogen.

Industrially and clinically relevant proteases and substrates include thrombin and serine proteases including PSA. A list of lysis enzymes is found in "Specificity of Proteolysis" Borivoj Keil (1992) Springer Verlag NY pp. 283-323. Useful ones are the serine and cysteine proteases. See also "Proteolytic Enzymes": a Practical Approach" R.J. Benyon & J.S. Bond (eds) 1989 Oxford University Press NY p232, pp. 241-249. Commercially significant proteases and protease inhibitors for which the present technology is relevant are available in serine, cysteine, aspartic and metallo types. The serine proteases include the endoproteinase-Arg-C, -Glu-C, Lys-C, factor Xa, proteinase K, subtilisin and trypsin, and the exopeptidases acylamino-acid-releasing enzyme, carboxypeptidase P, and carboxypeptidase Y. The cysteine proteases include the endopeptidases bromelain, cathepsin B, clostripain, papain, and the exopeptidases cathepsin C and pyroglutamate aminopeptidase. The aspartic proteases include the endopeptidases cathepsin D and pepsin. The metallo proteases include the endopeptidase thermolysin and the exopeptidases aminopeptidase M, carboxypeptidase-A, -B and leucine aminopeptidase. The listing is not intended to be exclusive and indicates the broad utility of the present invention. Other commercially useful proteases are listed in the publications cited above, which are included herein by reference. For example it also includes the endopeptide endoproteinase-Asp-N of unknown type.

In order that the nature of the present invention may be more clearly understood preferred forms thereof will now be described by reference to the following Examples and accompanying Figures.

Figure 1 shows a schematic representation of an embodiment of the device of the third aspect of the present invention. As can be seen from this Figure the device 10 includes a first zone 11 and a second zone 12. First zone 11 is provided with polymer beads 13 (carrier) linked to streptavidin 14 (probe) via a peptide linker 15. The peptide linker 15 is cleavable by the protease 16.

As shown in this Figure upon addition of the protease (or a nuclease) 16 the streptavidin 14 is released and passes to the second zone 12. Second

zone 12 includes a biosensor membrane 17 which detects the presence of streptavidin 14. Streptavidin 14 reaching biosensor membrane 17 causes a change in the impedance of the membrane.

Figure 2 shows an embodiment of the first and/or second aspect of the invention. As shown in Figure 2 the biosensor membrane 20 includes a membrane 21 and electrode 22. The membrane 21 has a first layer 23 and second layer 24 of arrays of amphiphilic molecules. Included in layer 24 is a first half membrane-spanning monomer 25 which is prevented from lateral diffusion within the membrane. Layer 23 includes a second half membrane-spanning monomer 26. The membrane also includes a membrane-spanning lipid 27 which is also prevented from diffusing laterally within the membrane. The second half membrane-spanning monomer 26 is linked to the membrane-spanning lipid 27 via a peptide 28. The peptide 28 is cleavable by protease 29. Upon cleavage of the peptide 28 by protease 29 the half membrane-spanning monomer 26 is free to diffuse laterally within the membrane. This results in a change in impedance of the membrane.

Examples

20 Example 1:

Protease cleavage of streptavidin-gramicidin linkage

- 25 1st layer: 9.3nM Linker Gramicidin B (Fig 3)
1.1 μ M Membrane Spanner Lipid D (Fig 4)
37 μ M MAAD (Fig 5)
75 μ M Linker Lipid A (Fig 6)
- 30 2nd layer: 10mM (DPE-PC (Fig 7):GDPE (Fig 8) = 7:3): Biotinylated Gramicidin E (Fig 9) = 66,677:1 in ethanol.

35 Electrodes with freshly evaporated gold (1000Å) on a chrome adhesion layer (200Å on glass microscope slides) were dipped into an ethanolic solution of the first layer components for 1 hour at room temperature, rinsed with ethanol, then stored at 4°C under ethanol until used for impedance measurements. The slide was clamped into a block

containing teflon coated wells which defined the area of the working electrode as approximately 16mm².

5 μ L of the second layer was added to the working electrode before addition of a 150 μ L volume of phosphate buffered saline (6.26mM NaCl, 59.4mM NaH₂PO₄·2H₂O, 2.53mM Na₂HPO₄·12H₂O, 50mM EDTA at pH 7.4; PBS). The electrode was then washed 4 times using PBS and raised to 60°C over a 30 minute period. Streptavidin was added to the sensor wells (5 μ L 0.01mg/ml in PBS) and incubated. The binding of streptavidin to the biotinylated gramicidin E gave a decrease in the admittance at minimum phase (Figure 10). After 15 minutes the excess streptavidin was washed out with PBS. Wells with no added streptavidin were run as controls.

Proteinase K was added to sensing and control wells to give end well concentration at 12.5mg/ml (Boehringer Mannheim D-68298 made in PBS). Addition of Proteinase K to control wells caused no significant change in membrane admittance characteristic. Sensor membranes to which streptavidin was bound exhibited an increase in admittance at minimum phase (Figure 11). The amount and rate of increase of admittance at minimum phase is related to the amount of proteinase K present in the test solution and therefore can be used to determine enzymatic activity in test solutions.

Example 2:

Dnase 1 cleavage of DNA-bound channels

25

1st layer: 9.3nM Linker Gramicidin B
1.1 μ M Membrane Spanner Lipid D
27.5nM Membrane Spanner Lipid C (Fig 12)
37 μ M MAAD
30 75 μ M Linker Lipid A

2nd layer: 14mM (DPE-PC:GDPE = 7:3): Biotinylated Gramicidin E
= 50,000:1 in ethanol.

35 Electrodes with freshly evaporated gold (1000Å) on a chrome adhesion layer (200Å) on glass microscope slides) were dipped into an

ethanolic solution of the first layer components for 1 hour at room temperature. rinsed with ethanol, then stored at 4°C under ethanol until used for impedance measurements. The slide was clamped into a block containing teflon coated wells which defined the area of the working electrode as approximately 16mm².

5 $5\mu\text{L}$ of the second layer was added to the working electrode before addition of a 180 μL volume of phosphate buffered saline (10mM NaH_2PO_4 , 1mM KH_2PO_4 , 137mM NaCl, 2.7mM KCl; PBS). The electrode was washed 4
10 times using PBS. These steps were carried out at room temperature. All the subsequent steps were carried out at 30°C. Streptavidin was added to all the wells (5 μL 0.01mg/ml in PBS) and allowed to react with biotinylated gramicidin E for 10-15 minutes before washing out excess unbound streptavidin with PBS, 5 μL of a 1:1 mixture of DNA probe F (200nM): DNA
15 probe G (200nM in PBS) was added to the sensor wells. A DNA non-specific binding probe H (5 μL 400 nM in PBS) was added to control wells. Binding probe H is non-complementary to the target DNA of interest and hence target DNA should not bind. The probes were allowed to react with streptavidin for 10-15 minutes then excess unbound probes were washed out with PBS.
20 100 μL of DNA target I (10nM) in PBS was added to each well. The binding of DNA target I to the sensor wells gave a decrease in the admittance at minimum phase, but no significant change in membrane admittance in control wells (Figure 13). After 15 minutes unbound DNA target I was washed out with DNase 1 activation buffer. DNase 1 activation buffer
25 consists of 50nM Tris. HCl, pH 7.6, 50nM NaCl, 10nM MgCl_2 , 10nM MnCl_2 , 0.2 mg/mL BSA. DNase 1 was added (2 μL 1mg/mL in a 50%w/v glycerol solution of 20mM Tris.HCl, pH 7.6, 1mM MgCl_2) to sensor and control wells. Addition of DNase 1 gave an increase in admittance at minimum phase for sensor wells, but no significant change for control wells (Figure 14). The
30 amount and rate of increase of admittance at minimum phase is related to the amount of DNase 1 present in the test solution and therefore can be used to determine enzymatic activity in test solutions.

DNA probe F:

5'biotinylated listeria probe DNA with a 31-atom phosphoramidite linker group between the biotin and DNA.

5 5'-bio-L-M-ATAGTTTTATGGGATTAGC-3'

DNA probe G:

5'biotinylated cholera toxin probe DNA with a 13-atom phosphoramidite linker group between the biotin and DNA.

10 5'-bio-L-CTCCGGAGCATAGAGCTTGGAGG-3'

DNA non-specific binding probe H:

15 5'biotinylated 15-mer oligonucleotide with a 31-atom phosphoramidite linker group between the biotin and DNA, which is non-complementary to all parts of the target DNA sequence.

5'-bio-L-M-ATTGCTACGTATACG-3'

20 DNA target I:


52 base DNA sequence containing the 19-base listeria sequence, a 10 base 'spacer' and the 23 base cholera toxin sequence.

25 5'-GCTAATCCCATAAACTATGCATGCATATCCCCAAGCTCTATGCTCCGGAG-3'


where:

bio = biotin

L=



M=



10 It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

CLAIMS:-

1. A biosensor for use in detecting the presence of an enzyme or enzymes in a sample, the biosensor comprising a membrane and means for determining the impedance of the membrane, the membrane having
5 ionophores therein to which are attached linkers, the linkers being cleavable by the enzyme or enzymes to be detected, the cleavage of the linker causing a change in the ability of ions to pass through the membrane via the ionophores.
2. A biosensor as claimed in claim 1 in which the linker is attached to
10 the membrane such that the ionophore is prevented from diffusing laterally within the membrane.
3. A biosensor as claimed in claim 2 in which the linker is attached to membrane spanning components provided in the membrane.
4. A biosensor as claimed in claim 3 in which the linker is attached to
15 the membrane spanning component via a ligand binding pair.
5. A biosensor as claimed in any one of claims 1 to 4 in which the membrane comprises a first and second layer of a closely packed array of amphiphilic molecules, a plurality of ionophores and a plurality of
20 membrane-spanning lipids prevented from lateral diffusion in the membrane, the ionophores comprising first and second half membrane spanning monomers, the first half membrane spanning monomers being provided in the first layer and the second half membrane spanning monomers being provided in the second layer, the first half membrane spanning monomers being prevented from lateral diffusion in the first layer,
25 the second half membrane spanning monomers being linked to the membrane spanning lipids via the linker.
6. A biosensor as claimed in any one of claims 1 to 5 in which the ionophores are gramicidin or analogues thereof.
7. A biosensor as claimed in any one of claims 1 to 6 in which the
30 enzyme to be detected is a protease.
8. A biosensor as claimed in claim 7 in which the protease is PSA.
9. A biosensor as claimed in any one of claims 1 to 6 in which the enzyme to be detected is a nuclease.
10. A biosensor for use in detecting the presence of an enzyme in a
35 sample, the biosensor comprising a membrane and means for determining the impedance of the membrane, the membrane having a plurality of

ionophores and a plurality of membrane-spanning components therein, the membrane-spanning components having attached thereto linker molecules to which are connected the ionophores, the linker molecules being cleavable by the enzyme to be detected, the cleavage of the linker molecules causing a
5 change in the ability of ions to pass through the membrane via the ionophores.

11. A biosensor as claimed in claim 10 in which the membrane comprises a first and second layer of a closely packed array of amphiphilic molecules and the membrane-spanning components are prevented from
10 lateral diffusion in the membrane.

12. A biosensor as claimed in claim 10 or claim 11 in which the ionophores comprise first and second half membrane spanning monomers, the first half membrane spanning monomers being provided in the first layer and the second half membrane spanning monomers being provided in the
15 second layer with the first half membrane spanning monomers being prevented from lateral diffusion in the first layer.

13. A biosensor as claimed in any one of claims 10 to 12 in which the ionophores are gramicidin or analogues thereof.

14. A biosensor as claimed in any one of claims 10 to 13 in which the
20 enzyme to be detected is a protease.

15. A biosensor as claimed in claim 14 in which the protease is PSA.

16. A biosensor as claimed in any one of claims 10 to 13 in which the enzyme to be detected is a protease.

17. A biosensor for the detection of enzymes comprising first and second
25 zones, means to allow addition of a sample suspected to contain a protease to the first zone, the first zone containing a probe linked to a carrier via a linker cleavable by the enzyme and means to allow passage of unlinked probe from the first zone to the second zone; the second zone including a membrane the impedance of which is dependent on the presence or absence
30 of the probe and means to measure the impedance of the membrane.

18. A biosensor as claimed in claim 17 in which the membrane comprises a first and second layer of a closely packed array of amphiphilic molecules and a plurality of ionophores comprising first and second half membrane spanning monomers, the first half membrane spanning monomers
35 being provided in the first layer and the second half membrane spanning monomers being provided in the second layer. the second half membrane

- spanning monomers being capable of lateral diffusion within the second layer independent of the first half membrane spanning monomers, the first half membrane spanning monomers being prevented from lateral diffusion in the first layer, and a ligand provided on at least the second half membrane spanning monomers, said ligand being reactive with the probe or a portion thereof, the binding of the probe to the ligand causing a change in the relationship between the first half membrane spanning monomers and the second half membrane spanning monomers such that the flow of ions across the membrane via the ionophores is allowed or prevented.
- 5 19. A biosensor as claimed in claim 17 or claim 18 in which the enzymes to be detected are proteases.
20. A biosensor as claimed in claim 19 in which the protease is PSA.
21. A biosensor as claimed in claim 17 or claim 18 in which the enzyme to be detected is a nuclease.
- 15 22. A biosensor as claimed in any one of claims 17 to 21 in which the half membrane spanning monomers are gramicidin or analogues thereof.
23. A biosensor as claimed in claim 17 in which the probe includes an ionophore.
24. A method of detecting the presence of an enzyme in a sample
- 20 comprising adding the sample to the biosensor as claimed in any one of claims 1 to 23 and measuring the change in impedance of the membrane.
25. A method as claimed in claim 24 in which the enzymes to be detected are proteases.
26. A method as claimed in claim 25 in which the protease is PSA.

1/13




FIGURE 1

2/13

For samples containing proteases, the protease activity liberates the tethered ion channel turning on the electrode.




FIGURE 2

3/13




Figure 3

4/13

R = H




Figure 4

5/13






Figure 5

6/13


**Figure 6**

7/13



GDPE

FIGURE 7



DPE-PC

Figure 8





Figure 9


9/13

Figure 10




10/13

Figure 11



11/13



R=





Figure 12


12/13

Figure 13



13/13

Figure 14



INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 97/00071

A. CLASSIFICATION OF SUBJECT MATTER		
Int Cl ⁶ : G01N 27/327, 27/333, 33/50, 33/574, 33/68, 33/96		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC : G01N 33/-, G01N 27/-		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU : IPC as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DERWENT : Biosensor, Ionophore, Ion Channel		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A, 96/12957 (PITTNER, F. & SCHALKHAMMER, T.) 2 May 1996. The whole document	1-26
P,X	AU,A, 38643/95 (AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RESEARCH INSTITUTE <i>et al</i>) 6 June 1996. Page 2 lines 18 to 34	1-6, 10-13, 17, 18 22-24
P,A	AU,A, 56403/96 (AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RESEARCH INSTITUTE <i>et al</i>) 29 November 1996. Page 2 lines 18 to 34	1-26
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 21 May 1997		Date of mailing of the international search report 29 MAY 1997
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (06) 285 3929		Authorized officer D.A. Lally D.A. Lally Telephone No.: (06) 283 2533

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 97/00071

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A, 95/16206 (BIOSYSTEMS TECHNOLOGY (CORP)) 15 June 1995. Page 12, lines 7 to 12	1, 17
A	WO,A, 95/08637 (UNIVERSITY OF WASHINGTON STATE RESEARCH FOUNDATION) 30 March 1995	1-26
A	US,A, 5368712 (SYNPORIN TECHNOLOGIES, INC) 29 November 1994. Page 5 line 11 to 16	1-26
A	AU,A, 65327/94 (AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RESEARCH INSTITUTE <u>et al</u>) 8 November 1994. Page 2 lines 18 to 34	1-26
A	AU,A, 56188/94 (AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RESEARCH INSTITUTE <u>et al</u>) 22 June 1994. Page 1 line 25 to page 2 line 6	1-26
A	AU,A, 51444/93 (AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RESEARCH INSTITUTE <u>et al</u>) 26 April 1994. Page 4 line 2 to page 29 line 35.	1-26
A	EP,A, 342382 (GENERAL ELECTRIC COMPANY) 23 November 1989. Columns 4 to 6.	1-26
A	GB,A, 2195450 (UNITED KINGDOM ATOMIC ENERGY AUTHORITY) 7 April 1988. Lines 59 to 78	1-26

Information on patent family members

International Application No.

PCT/AU 97/00071

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

[illegible]

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)